Table 5.
Relationships between HMGB1 expression and clinicopathological parameters.
| HMGB1 IHC | p value | ||
|---|---|---|---|
| Weak | Strong (%) | ||
| Hydronephrosis | |||
| Mild | 41 | 18 (30.5%) | 0.1169 |
| Severe | 14 | 13 (48.2%) | |
| Urine cytology | |||
| Negative | 28 | 12 (30.0%) | 0.2746 |
| Positive | 12 | 19 (41.3%) | |
| T stage | |||
| Ta-T1 | 42 | 7 (14.3%) | < 0.0001 |
| T2-T4 | 13 | 24 (64.9%) | |
| Histological grade | |||
| Low grade | 26 | 3 (10.3%) | 0.0002 |
| High grade | 29 | 28 (49.1%) | |
| Lymphovascular invasion | |||
| Not evident | 43 | 16 (27.1%) | 0.0116 |
| Evident | 12 | 15 (55.6%) | |
| Concomitant CIS | |||
| No | 45 | 18 (28.6%) | 0.0184 |
| Yes | 10 | 13 (56.5%) | |
HMGB1 high mobility group box 1, IHC immunohistochemistry, CIS carcinoma in situ.
The significance of bold means p < 0.05.